Fmr LLC Trims Stock Holdings in Synlogic, Inc. (NASDAQ:SYBX)

Fmr LLC lowered its stake in Synlogic, Inc. (NASDAQ:SYBX) by 27.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 166,724 shares of the biotechnology company’s stock after selling 63,485 shares during the quarter. Fmr LLC owned about 1.42% of Synlogic worth $248,000 at the end of the most recent quarter.

Synlogic Price Performance

Shares of SYBX opened at $1.42 on Friday. The firm has a 50-day simple moving average of $1.42 and a two-hundred day simple moving average of $1.49. The stock has a market cap of $16.61 million, a PE ratio of -0.34 and a beta of 0.83. Synlogic, Inc. has a 1-year low of $1.22 and a 1-year high of $5.12.

Synlogic (NASDAQ:SYBX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.17. Synlogic had a negative return on equity of 207.84% and a negative net margin of 2,284.65%. As a group, sell-side analysts expect that Synlogic, Inc. will post -2.71 earnings per share for the current fiscal year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.